

Akums launches drug for enlarged prostate & erectile dysfunction treatment

14 September 2023 | News

Advancing healthcare solutions for patients grappling with benign prostatic hyperplasia and erectile dysfunction



Akums Drugs and Pharmaceuticals, New Delhi-based contract manufacturing and development organisation (CDMO), has introduced an advancement in healthcare — the Tamsulosin + Tadalafil Capsule — to the Indian market.

This innovative combined therapy, delivered in a fixed dose combination within a hard gelatin capsule, marks an important achievement for the company. Notably, Akums has become the first CDMO to obtain approval for the unique formulation of Tamsulosin 0.4/0.4mg + Tadalafil 2.5/5mg, as sanctioned by the Drug Controller General of India (DCGI).

Tamsulosin is a selective α_1A -adrenergic receptor antagonist. The effects of tamsulosin are targeted for the smooth muscle receptors of the prostate and urethra. Blocking this receptor relaxes the smooth muscle of the bladder and urethra to improve urine flow. It is primarily used when an enlarged prostate impedes normal urine flow and bladder emptying.

In tandem, the mechanism of action for Tadalafil centers on the inhibition of PDE5, a crucial enzyme located in the vascular smooth muscle cells of corpus cavernosum. By impeding cGMP hydrolysis, Tadalafil promotes cGMP accumulation and the relaxation of vascular smooth muscle, facilitating the development of a physiologically-induced erection, contingent upon sexual stimulation.